ClinicalTrials.gg
CompletedNCT00792467Updated May 11, 2021Results posted

Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

A Phase 1/2 interventional study of ITF2357 in Hodgkin's Lymphoma, sponsored by Italfarmaco. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Italfarmaco · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Hodgkin Disease with a site in Italy — 11 open to participants now, 17 under way, 3 of them phase 3. Hodgkin Disease · Italy.

Enrollment
63rd of 72
24 · median 106
Started
2008
with 6 others
Phase 1/2
17 of 98
1 open now
Registered
28th of 98
by date

Among the 98 studies in Hodgkin Disease with a site in Italy, this one is the 63rd largest by enrollment of the 72 interventional ones that give a count, is one of 7 that started in 2008, is one of 17 in phase 1/2, and was the 28th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

11 of the 98 studies in Hodgkin Disease with a site in Italy are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Hodgkin Disease with a site in Italy, or all of them as a file.
02

Study summary

This study has the following objectives:

Primary Objective

  • To evaluate the anti-lymphoma efficacy of daily oral doses of ITF2357 followed by intravenous Mechlorethamine administered to patients with refractory/relapsed Hodgkin's lymphoma.

Secondary Objective

  • To evaluate the safety and tolerability of multiple courses of ITF2357 followed by Mechlorethamine in a population of chemotherapy pretreated patients.
Read the detailed description

This is a single-center, open label, phase II study aimed at testing the activity of multiple cycles of ITF2357 followed by Mechlorethamine administered to patients with relapsed/refractory Hodgkin's lymphoma.

Patients will receive a maximum of twelve 3-week cycles of ITF2357 followed by Mechlorethamine according to the following schema:

  • ITF2357, 50 mg every 6 hours, per os, days 1 - 3
  • Mechlorethamine, 6 mg/sqm, intravenously , day 4 Study therapy will be administered every 21 days as long as there is no evidence of progressive disease or unacceptable adverse events or patient's request to discontinue treatment occurs, but in any case for a maximum of 12 cycles.

Decision regarding the continuation of ITF2357/Mechlorethamine therapy will be made on (i)the basis of tumor reassessment following cycles 2, 6, 9, and 12 and (ii) the occurrence of toxicity. Tumor response will be evaluated according to the International Working Group response criteria HL.

Treatment will be administrated on an outpatient basis and patients will be followed regularly with physical and laboratory tests, as specified in the protocol; in case of hospitalisation, the treatment will be continued or interrupted according to the Investigators' decision.

The study will accrue 23 patients evaluable for efficacy and the anticipated duration of the study is about 24 months.

Histone deacetylases (HDACs) are enzymes involved in the remodeling of chromatin, and have a key role in the epigenetic regulation of gene expression. In addition, the activity of non-histone proteins can be regulated through HDAC-mediated hypoacetylation. In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes associated with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclinical studies.

Hodgkin's lymphoma (HL) is a relatively uncommon lymphoma histotype, with an incidence in Italy of approximately 1700 new cases per year (approximately 12% of all lymphomas). Combination chemotherapy with or without radiotherapy cures approximately 70 percent of advanced-stage HL. Fifty percent of the failing patients can be salvaged by second line chemotherapy (mainly high-dose regimens), while the remaining patients eventually die by disease progression. The development of an effective salvage regimen for this refractory/resistant population represents a true unmet medical need.

The use in the latter patient subset of HDAC inhibitors, like ITF2357, is supported by several considerations. Namely: (1) a related hydroxamate, SAHA, has shown activity in this clinical condition; (2) the drug markedly inhibits the production of several cytokines, and cytokine production in HL granuloma has a defined role in the pathogenesis of HL; (3) an effective treatment for refractory/relapsed HL is presently lacking; (4) ITF2357, up to 200 mg daily per os, has shown a favorable toxicity profile. All the above mentioned arguments represent a strong rationale prompting the use of ITF2357 in this patient population.

03

Conditions studied

  • Hodgkin's Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written ;
  • Age ≥18 years;
  • confirmed diagnosis of Hodgkin's lymphoma;
  • Subjects who have failed or subsequent-line salvage chemo- radiotherapy regimens for whom no other treatment options of proven efficacy can be given;
  • Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements;
  • ≥1500/µL; count ≥75000/µL;
  • ≥9 g/dL (may not be transfused or treated with erythropoietin to maintain or exceed this level);
  • Total ≤1.6 mg/dL; or ALT ≤2.5 times the ;
  • Serum creatinine ≤2.0 mg/dL or >50 mL/min;
  • Serum Potassium and Magnesium within normal limits;
  • Subjects with at least one bi-dimensional lesion measurable by CT-scan or MRI, according to the Revised Response Criteria for Malignant Lymphoma of the International Working Group (J Clin Oncol, 25:579-586, 2007);
  • performance status of 0 or 1;
  • Use of an effective means of for women of and men with partners of childbearing potential;
  • of >3 months;
  • Subjects receiving intravenous Mechlorethamine (6 mg/sqm) as single agent at least 4 weeks before study entry;
  • Willingness and capability to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Active bacterial or mycotic infection requiring antimicrobial treatment
  • Pregnancy or lactation
  • Anticancer chemotherapy or radiotherapy during the study or within 4 weeks of study entry.
  • A marked baseline prolongation of /QTc interval (e.g. repeated demonstration of a QTc interval > 450 ms, according to Bazett's correction formula - see appendix I for the formula)
  • Use of concomitant medications that prolong the QT/QTc interval (see appendix H for full list)
  • cardiovascular disease including:
  • Uncontrolled hypertension, myocardial infarction, unstable angina
  • (NYHA) Grade II or greater congestive heart failure
  • History of any cardiac arrhythmia requiring medication (irrespective of its severity)
  • A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Positive blood test for , and
  • Identification of viral DNA by quantitative PCR for EBV and JC virus.
  • History of other diseases, metabolic dysfunctions, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates use of an drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ITF2357

    Patients received the following therapy cycle * ITF2357, 50 mg every 6 hours, per os, days 1 - 3; * Mechlorethamine, 6 mg/sqm, intravenously , day 4. Therapy was administered every 21 days as long as there was no evidence of progressive disease or unacceptable toxicity, but in any case for a maximum of 12 cycles. The mean number of complete treatment cycles received by patients was 5.25, with a minimum of 1 cycle and a maximum of 12 cycles.

    Drug: ITF2357

Interventions

  • ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.

    Also known as: Givinostat, histone deacetylase inhibitor

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    OR rate among patients treated is defined according to the Revised Response Criteria for Malignant Lymphoma of the International Working Group. In medicine, a response rate is the percentage of patients whose cancer shrinks or disappears after treatment. The FDA definition of ORR is the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period. The tumor objective response rate (ORR) is an important parameter to demonstrate the efficacy of a treatment in oncology. The ORR is valuable for clinical decision making in routine practice and a significant end-point for reporting the results of clinical trials.

    Time frame: At each 21-day cycle for a maximum of 12 cycles

  2. Proportion of Responders (Complete -CR- or Partial PR-)

    Complete responder (CR) and partial responder (PR) among patients treated are defined according to the Revised Response Criteria for Malignant Lymphoma of the International Working Group. CR is defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is defined as regression of measurable disease and no new sites. The frequencies of patients achieving objective response (i.e. subjects whose best overall response was CR or PR) and the frequencies of patients who did not achieve an objective response (i.e.subjects whose best overall response was equal to stable disease - SD, progressive disease - PD - or not evaluable) in ITT and PP populations are reported. NED= no evidence of disease

    Time frame: At each 21-day cycle for a maximum of 12 cycles

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from the 1st day of the 1st cycle of treatment until objective tumor progression or death. It included deaths, thus could be correlated to overall survival. If a patient did not have disease progression, PFS was censored at the date of last available tumor assessment (including those at end of study or follow-up visit).

    Time frame: From the first day of the first cycle of treatment until objective tumor progression or death, whichever came first, assessed up to 450 days from the start of the first cycle of treatment

  2. Time To Response (TTR)

    TTR is defined as the time from the 1st day of the 1st cycle until the date of achieving a response (CR or PR). In case of no objective response, TTR was censored at the date of last available tumor assessment (including those at end of study or follow-up visit).

    Time frame: From the first day of the first cycle until the date of achieving a response assessed up to 250 days from the start of the first cycle of treatment

  3. Response Duration (RD):

    Duration of objective response (CR or PR) was applied only to patients whose best overall response was CR or PR.

    Time frame: From the first day of the first cycle of treatment until objective tumor progression or death, whichever came first, or last available tumor assessment (assessed up to 350 days from the start of the first cycle of treatment).

07

Results

Posted Apr 19, 2021

Participant flow

Patients enrolled were 24 subjects of both genders, age ≥18 years, with histologically confirmed diagnosis of Hodgkin's lymphoma and refractory or relapsed.

Participant flow — Overall Study
MilestoneITF2357
Started24
Completed2
Not completed22
Withdrew: Progression of disease17
Withdrew: Adverse event1
Withdrew: Patient request1
Withdrew: Lost to follow-up1
Withdrew: Patient achieved a pr and allogenic transplant was performed1
Withdrew: Patient in cr and hla-matched donor available. allogenic sct performed1

Outcome measures

PrimaryObjective Response Rate (ORR)

OR rate among patients treated is defined according to the Revised Response Criteria for Malignant Lymphoma of the International Working Group. In medicine, a response rate is the percentage of patients whose cancer shrinks or disappears after treatment. The FDA definition of ORR is the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period. The tumor objective response rate (ORR) is an important parameter to demonstrate the efficacy of a treatment in oncology. The ORR is valuable for clinical decision making in routine practice and a significant end-point for reporting the results of clinical trials.

Time frame:
At each 21-day cycle for a maximum of 12 cycles
Reported as:
Number · percentage of patients
Objective Response Rate (ORR)
percentage of patientsITT PopulationPP Population
Objective Response achieved25.0037.50
Objective Response not achieved75.0062.50
PrimaryProportion of Responders (Complete -CR- or Partial PR-)

Complete responder (CR) and partial responder (PR) among patients treated are defined according to the Revised Response Criteria for Malignant Lymphoma of the International Working Group. CR is defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is defined as regression of measurable disease and no new sites. The frequencies of patients achieving objective response (i.e. subjects whose best overall response was CR or PR) and the frequencies of patients who did not achieve an objective response (i.e.subjects whose best overall response was equal to stable disease - SD, progressive disease - PD - or not evaluable) in ITT and PP populations are reported. NED= no evidence of disease

Time frame:
At each 21-day cycle for a maximum of 12 cycles
Reported as:
Number · percentage of participants
Proportion of Responders (Complete -CR- or Partial PR-)
percentage of participantsITT PopulationPP Population
CR/NED4.176.25
PR20.8331.25
SD29.1725.00
PD37.5037.50
Not evaluable8.330
SecondaryProgression-Free Survival (PFS)

PFS is defined as the time from the 1st day of the 1st cycle of treatment until objective tumor progression or death. It included deaths, thus could be correlated to overall survival. If a patient did not have disease progression, PFS was censored at the date of last available tumor assessment (including those at end of study or follow-up visit).

Time frame:
From the first day of the first cycle of treatment until objective tumor progression or death, whichever came first, assessed up to 450 days from the start of the first cycle of treatment
Reported as:
Mean · Days
Progression-Free Survival (PFS)
DaysITT PopulationPP Population
Progression-Free Survival (PFS)164.53 ± 28.66183.94 ± 39.38
SecondaryTime To Response (TTR)

TTR is defined as the time from the 1st day of the 1st cycle until the date of achieving a response (CR or PR). In case of no objective response, TTR was censored at the date of last available tumor assessment (including those at end of study or follow-up visit).

Time frame:
From the first day of the first cycle until the date of achieving a response assessed up to 250 days from the start of the first cycle of treatment
Reported as:
Mean · Days
Time To Response (TTR)
DaysITT PopulationPP Population
Time To Response (TTR)123.52 ± 11.70114.34 ± 14.81
SecondaryResponse Duration (RD):

Duration of objective response (CR or PR) was applied only to patients whose best overall response was CR or PR.

Time frame:
From the first day of the first cycle of treatment until objective tumor progression or death, whichever came first, or last available tumor assessment (assessed up to 350 days from the start of the first cycle of treatment).
Reported as:
Mean · Days
Response Duration (RD):
DaysITT PopulationPP Population
Response Duration (RD):199.96 ± 42.77199.96 ± 42.77

Adverse events

Collected over Throughout the course of the study, up to a maximum of 12 cycles, an average of 1 year.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ITF23573/24 (12.5%)1/24 (4.2%)24/24 (100%)
Most frequent serious events
Most frequent serious events
EventITF2357
CoughRespiratory, thoracic and mediastinal disorders1/24
DyspnoeaRespiratory, thoracic and mediastinal disorders1/24
FeverRespiratory, thoracic and mediastinal disorders1/24
Most frequent other events
Showing 10 of 42
Most frequent other events
EventITF2357
ThrombocytopeniaCardiac disorders16/24
AnaemiaBlood and lymphatic system disorders12/24
NeutropeniaCardiac disorders11/24
NauseaGastrointestinal disorders7/24
PyrexiaGeneral disorders7/24
AstheniaGeneral disorders6/24
CoughRespiratory, thoracic and mediastinal disorders6/24
DiarrhoeaGastrointestinal disorders5/24
VomitingGastrointestinal disorders5/24
DyspnoeaRespiratory, thoracic and mediastinal disorders5/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ITF2357
<=18 years0
Between 18 and 65 years24
>=65 years0
Age, Continuous
Age, Continuous(years)ITF2357
Mean35.83 ± 14.49
Sex: Female, Male
Sex: Female, Male(Participants)ITF2357
Female5
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ITF2357
Hispanic or Latino23
Not Hispanic or Latino1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)ITF2357
Italy24
08

Study locations

1 site
  • Istituto Nazionale per la Cura e lo Studio dei Tumori
    Milano, 20133, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Jul 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2021, 10 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2008
First posted
Nov 18, 2008
Start
Feb 2008
Primary completionActual
Jul 2010
CompletionActual
Sep 2010
Results first posted
Apr 19, 2021
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00792467
Lead sponsor
Italfarmaco
Responsible party
Sponsor
First posted
Nov 18, 2008
Start date
Feb 2008
Primary completion
Jul 2010
Completion
Sep 2010
Results posted
Apr 19, 2021
Last update
May 11, 2021

Study contacts

Alessandro Massimo Gianni, MD
principal investigator · Istituto Nazionale per la Cura e lo Studio dei Tumori, Milano, Italy

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion